Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis.

Abstract

Several studies have assessed the association of CD95L polymorphism with cervical cancer risk, but the data lack the power to provide compelling evidence. In this study, we aimed to clarify the association through a meta-analysis. A comprehensive search was conducted in PubMed, Embase, and Web of Science. The fixed-effects model was used to calculate odds ratio (OR) with 95 % confidence intervals (CIs). A total of five papers with six case-control studies were derived and finally included in this meta-analysis. The overall estimate did not reveal any significant association between CD95L -844C/T polymorphism and cervical cancer risk. Subgroup analysis in Asian population indicated nonsignificant nevertheless potentially increased risk in CC genotype carriers in comparison with the carriers of CT+TT genotypes (ORCC vs. CT+TT=1.16, 95 % CI=0.99-1.36, P for heterogeneity=0.231). Based on current epidemiological studies, this meta-analysis suggests that CD95L polymorphism may not be a risk factor contributing to cervical cancer development.

• Authors: Jing Zhu, Lei Lu, Xiang Cheng, Rongkai Xie, Zhengqiong Chen, Youfei Li, Guilan Lin, Jianmei Liu, Ying Yang
• Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol) Vol. 35 Issue 6 Pg. 5137-42 (Jun 2014) ISSN: 1423-0380 [Electronic] Netherlands
• PMID: 24619598 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Fas Ligand Protein

Topics

• Case-Control Studies
• Fas Ligand Protein (genetics)
• Female
• Genetic Predisposition to Disease
• Genotype
• Humans
• Polymorphism, Genetic
• Risk
• Uterine Cervical Neoplasms (etiology, genetics)